The emergence of ZN.1 is an evolutionary change in the COVID pandemic. Why is it important?

Since its detection in August 2023, the JN.1 variant of Covid has spread widely. It has become dominant in Australia and around the world, causing the largest COVID wave seen in many areas in at least the last year. The World Health Organization (WHO) classified JN.1 as a variant of concern in December 2023 and strongly stated in January that COVID is an ongoing global health threat with worrying potential for long-term health consequences. Is causing disease. JN.1 is important. First as a pathogen – this is a surprisingly new variant of SARS-CoV-2 (the virus that causes COVID) and is rapidly replacing other circulating strains (Omicron XBB). It is also important because of what it says about the evolution of Covid.

In general, SARS-CoV-2 variants look largely the same as before, accumulating only a few mutations at a time that give the virus a meaningful advantage over its parent virus. However, sometimes, as was the case when Omicron (B.1.1.529) emerged two years ago, variants suddenly emerge that have markedly different characteristics than before. This has important implications for disease and transmission. Until now, it was unclear whether this step-change development would happen again, especially given the ongoing success of the continuously evolving Omicron variants. JN.1 is so different and is causing such a wave of new infections that many are wondering whether WHO will have to recognize JN.1 as the next variant of concern. In any case, with JN.1 we have entered a new phase of the pandemic.

Where did JN.1 come from? The story of JN.1 (or BA.2.86.1.1) begins in mid-2023 with the emergence of its parent BA.2.86, which originated from the much earlier (2022) Omicron sub-variant BA.2. Long-lasting infections that can remain unresolved for months (if not years in some people) likely play a role in the emergence of these phase-change variants. In chronically infected people, the virus silently tests and eventually maintains several mutations that help it evade immunity and survive in that person. For BA.2.86, this resulted in more than 30 mutations in the spike protein (a protein on the surface of SARS-CoV-2 that helps it attach to our cells). The sheer volume of infections occurring globally sets the stage for major viral developments. The mutation rate in SARS-CoV-2 remains very high.

Accordingly, JN.1 itself is already variable and rapidly evolving. How is JN.1 different from other variants? BA.2.86 and now ZN.1 are behaving in a way that appears unique in laboratory studies in two ways. The first relates to how the virus evades immunity. JN.1 has inherited more than 30 mutations in its spike protein. It has also acquired a new mutation, L455S, which further reduces the ability of antibodies (part of the immune system’s protective response) to attach to the virus and prevent infection. The second involves changes in the way JN.1 enters and replicates in our cells. Without going into molecular details, recent high-profile lab-based research from the US and Europe saw BA.2.86 entering cells from the lungs in a manner similar to pre-Omicron variants like Delta.

However, in contrast, preliminary work by Australia’s Kirby Institute using different techniques reveals replication characteristics that align better with the Omicron lineage. Further research is important to resolve these different cell entry findings as they have implications for where the virus may prefer to replicate in the body, which could influence disease severity and transmission. Whatever the case, these findings show that JN.1 (and SARS-CoV-2 in general) can not only make its way around our immune system, but also infect cells and transmit effectively. Finding new ways to do it. We need to further study how it works in people and how it affects clinical outcomes.

Is JN.1 more serious? The step-change evolution of BA.2.86, combined with the immune-suppressing characteristics in JN.1, has given the virus a global evolutionary advantage over the XBB.1-based lineages encountered in 2023. Despite these characteristics, evidence suggests that our adaptive immune system can still recognize and respond effectively to BA.286 and JN.1. Updated monovalent vaccines, tests, and treatments remain effective against JN.1. There are two elements of severity: first if it is intrinsically more severe (worse disease with infection in the absence of any immunity) and second if the transmission of the virus is greater, causing more illness and deaths, simply because it is more contagious. Infects people. The second element is certainly the case with the JN.1.

what next? We simply don’t know whether this virus is on the evolutionary path to becoming the next common cough and cold, nor do we have any idea what that time frame might be. While examining the trajectories of four historical coronaviruses can give us a glimpse of where we are headed, this should be considered only one possible path. The emergence of JN.1 underlines that we continue to face the COVID pandemic and it appears to be the way forward for the foreseeable future. We are now in a new pandemic phase: post-emergency. Nevertheless, COVID remains the leading infectious disease causing harm globally, both from acute infection and long-term COVID.

At a societal and individual level, we need to rethink the risks of accepting wave after wave of infection. Overall, this underlines the importance of comprehensive strategies to reduce COVID transmission and impacts, with minimal stress (such as clean indoor air interventions). People are advised to continue taking proactive steps to protect themselves and those around them. It is important that we continue global surveillance for better pandemic preparedness for emerging threats and better response to existing threats. The under-representation of low- and middle-income countries is a worrying point.

Disclaimer: IndiaTheNews has not edited this news. This news has been published from PTI-language feed.

---

---